StreetAlpha.app
Home › Stocks › SLDB

Solid Biosciences Inc. (SLDB)

Healthcare
$6.25
▼ −2.95%
LAST CLOSE · NOV 20

Solid Biosciences develops gene therapy candidates for rare neuromuscular and cardiac diseases, starting with Duchenne muscular dystrophy. It last closed at $6.25 on Nov 20, down 2.95% on the day. For the quarter ended Sep 2026, SLDB reported EPS of -$0.36. Over its last 8 reports the stock moved an average of 12.4% the session after earnings. Over the last 12 months SLDB insiders bought $0 of stock on the open market and sold $2.7M, according to SEC Form 4 filings.

AI Auto Pilots
Is SLDB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SLDB.

Key Stats

Last 12 months
Results
Net income
−$215.3M
EPS (diluted)
−$1.76
Free cash flow
−$200.3M
Valuation
Market cap
$697.6M
111.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$126.0M
At Sep 30
Shareholder equity
$342.1M
Shares outstanding
111.6M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$72.2M−$72.2MFY2021FY2022: −$86.0M−$86.0MFY2022FY2023: −$96.0M−$96.0MFY2023FY2024: −$124.7M−$124.7MFY2024FY2025: −$174.3M−$174.3MFY2025

From SLDB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Last report
Mar 6
2026 · next date not set yet
Reported EPS
-$0.36
Quarter ended Sep 2026
Year ago EPS
-$0.48
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.02Dec '24Mar 2025: -$0.59Mar '25Jun 2025: -$0.42Jun '25Sep 2025: -$0.48Sep '25Dec 2025: -$0.53Dec '25Mar 2026: -$0.52Mar '26Jun 2026: -$0.38Jun '26Sep 2026: -$0.36Sep '26Latest -$0.36
Revenue by quarter
Not enough quarters on file yet.
How SLDB moved after its last 8 reports
Average move the session after a report ±12.4%
Mar 6, 2026After the close+18.8%
Nov 3, 2025After the close−15.3%
Feb 18, 2025Time not announced+31.5%
Jan 8, 2024Time not announced+7.6%
Jan 9, 2023Time not announced+2.6%
Aug 11, 2022Time not announced+3.6%
Apr 27, 2022Time not announced−17.0%
Jan 10, 2022Time not announced−3.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SLDBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SLDB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SLDB

Technical Analysis

SLDB · as of the Nov 20 close · updated each morning
Downtrend

The stock is 4% below its 20 day and 10% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 45). The nearest support is the Pivot S1 at $6.12, and the nearest resistance the Pivot at $6.33.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 7.5%/day
Key levels
$11.4552 week high+83.2%
$8.08100 day average+29.3%
$7.68200 day average+22.9%
$6.8850 day average+10.1%
$6.58Swing high (Oct 21)+5.3%
$6.5020 day average+4.0%
$6.46Pivot R1+3.4%
$6.33Pivot+1.3%
$6.25Last close
$6.12Pivot S1−2.1%
$5.83Swing low (Nov 2)−6.7%
$4.4452 week low−29.0%
Indicators
RSI (14)44.53Middle of its rangeNeutral
MACD-0.09Below its signal lineBearish
Stochastic22.9Middle of its rangeNeutral
ADX (14)18.2No clear trend
Williams %R-87.0Oversold below −80, overbought above −20Oversold
CCI (20)-36.7Oversold below −100, overbought above 100Neutral
Rate of change−5.2%Change over 10 sessionsBearish
ATR (14)$0.47Typical daily range, 7.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SLDB

What happened before

See how SLDB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SLDB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SLDB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SLDBHow many large options trades hit SLDB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SLDB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲80 buying vs 68 selling
  • ▲Held by funds +4.0 pts
  • ●Funds holding +1
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding158157+0.6%
In funds' top 10330.0%
Held by funds106.7%102.6%+4.0 pts
New / increased25 / 5541 / 56−17.5%
Reduced / sold out45 / 2337 / 24+11.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SLDB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SLDB Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.7M27 sales · 7 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $117K2026-01 sold $37K2026-02 sold $2.5M2026-10 sold $25KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 19Gabriel BrooksChief Medical OfficerSale plan4,374$5.62$25K
Feb 18Kevin TanCFO & TreasurerSale plan5,404$5.82$31K
Feb 18David T HowtonCOOSale plan7,469$5.82$43K
Feb 18Paul HerzichChief Technology OfficerSale plan3,616$5.82$21K
Feb 18Ilan GanotDirectorSale plan2,658$5.82$15K
Feb 18Jessie HanrahanChief Regulatory OfficerSale plan4,134$5.82$24K
Every insider buy and sale for SLDB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SLDB insider trades →

From SEC Form 4 filings by SLDB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLDB is in one of them and how their past SLDB trades turned out.

SLDB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SLDB in an article yet. Here's the latest on the wider market.

About Solid Biosciences

Solid Biosciences is a life sciences company based in Charlestown, Massachusetts, that develops gene therapy candidates for rare neuromuscular and cardiac diseases. Its lead candidate, SGT-003, is designed to treat Duchenne muscular dystrophy by delivering a gene that produces a smaller version of the dystrophin protein. The company is also developing candidates for Friedreich's ataxia and other genetic heart diseases. Its work is aimed at patients living with these rare conditions, many of whom have few treatment options.

Headquarters
Charlestown, MA